Guidelines on the Use of Systemic Therapy in Patients with Advanced Thyroid Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Recent advancements in understanding molecular alterations in thyroid cancer.
• Rapid increase in targeted systemic therapies for advanced thyroid cancer, including multi-kinase inhibitors and specific agents (RET, BRAF, MEK, ALK, NTRK).

Purpose of the Study:

• To provide guidelines for managing advanced thyroid cancer with novel targeted therapies.
• To support clinicians in making treatment decisions, managing toxicities, and arranging molecular genetic testing.
• To offer information for both patients and clinicians on optimal timing for initiating treatment.

Main Methods:

• Development of clinical guidelines based on current understanding of molecular alterations and targeted therapies.
• Review of novel agents, their toxicities, and molecular testing strategies.
• Consideration of disease progression and optimal treatment initiation timing.

Main Results:

• Introduction of multi-kinase inhibitors and specific inhibitors (RET, BRAF, MEK, ALK, NTRK) has shifted advanced thyroid cancer management.
• Need for adaptation by oncologists to safely supervise novel treatments and manage emerging toxicities.
• Importance of molecular genetic testing and determining optimal treatment initiation for indolent, progressive thyroid cancer.

Conclusions:

• Guidelines are crucial for supporting clinicians and patients in navigating the complexities of advanced thyroid cancer treatment.
• Effective management requires understanding novel agents, managing toxicities, and strategic molecular testing.
• Optimizing treatment timing is essential for patients with indolent, yet progressive, thyroid cancer.